Company Overview
Veradermics, Incorporated operates as a biopharmaceutical company dedicated to the development of novel therapeutics for dermatologic and aesthetic conditions, with a specific focus on treating Pattern Hair Loss in both adult and pediatric populations. The company is situated within the Healthcare sector and the Biotechnology industry, a classification that implies a business model centered on high-risk research and development rather than established manufacturing or service delivery. The company holds a market capitalization of $2.07B, while its annual revenue and total employee count are not disclosed in the available financial records. These valuation metrics indicate that the market assigns a significant premium to the company's intellectual property and pipeline potential, suggesting that investors value the enterprise based on future therapeutic outcomes rather than current operational scale or historical profitability.
Financial Health
The company reports a net income of $-61,641,000 over the trailing twelve months, while specific figures for revenue and EBITDA are not available for disclosure in the current dataset. The substantial gap between reported revenue and net income, evidenced by the negative net income despite positive cash reserves, reveals a cost structure where research, development, and administrative expenses heavily outweigh current operational revenues. Free cash flow and operating metrics such as EBITDA are not reported, which suggests the company is in a capital-intensive growth phase where reinvestment in clinical trials and product development consumes available liquidity. All three margin metrics—gross margin, operating margin, and profit margin—are recorded at 0.0%, indicating that the company has not yet achieved commercial profitability or that the financial reporting model reflects pre-revenue or pre-commercialization status. The company maintains a cash position of $53.08M with no disclosed debt, resulting in a debt-to-equity ratio that is not applicable, which paints a picture of a balance sheet that is conservative regarding leverage but reliant on cash reserves to fund operations. A current ratio of 3.29 is reported, indicating a strong short-term liquidity position where current assets significantly exceed current liabilities. Return on equity, return on assets, and other return metrics are not available, meaning these specific efficiency indicators cannot be calculated to evaluate management effectiveness at this time.
Valuation Assessment
The company does not have a trailing P/E ratio or a standard forward P/E ratio reported in the conventional sense, though a forward P/E figure of -21.39 is listed, which typically signals that the stock price is not supported by current earnings per share. The price-to-book ratio stands at -0.45, a negative figure that indicates the market capitalization is below the book value of equity, often seen in biotechnology firms with significant intangible assets or negative shareholder equity due to accumulated losses. Alternative valuation metrics such as the price-to-sales ratio and EV/EBITDA are not available, suggesting that traditional multiple-based comparisons are not currently applicable for assessing the company's relative value. The stock has traded within a 52-week range with a high of $63.03 and a low of $32.00, providing a historical context for price volatility over the past year. Without a specific current price to calculate the exact percentage below the high, the available data confirms the stock's movement within this established band, reflecting market sentiment regarding the company's development progress. The beta value is not disclosed, preventing a direct assessment of the stock's volatility relative to the broader market index based on the provided facts.
Growth & Income
Revenue growth year-over-year and earnings growth year-over-year are not disclosed, so it is not possible to quantify the rate at which earnings are growing relative to revenue from the available data. Because the company does not pay a dividend, with a dividend yield of N/A and a payout ratio of 0.0%, it follows a strategy of reinvesting all available earnings and cash reserves into research, development, and pipeline expansion rather than distributing income to shareholders. The absence of dividend payments combined with the lack of reported revenue growth metrics indicates that the company is prioritizing long-term asset accumulation and clinical advancement over immediate income generation for investors. The overall growth and income profile is characterized by a total reliance on capital appreciation potential driven by the success of its dermatologic therapeutics, with no current income stream to support shareholder distributions.